Yovino S et al. (2005) An association between preoperative anemia and decreased survival in earlystage non-small-cell lung cancer patients treated with surgery alone. Int J Radiat Oncol Biol Phys 62: 1438–1443
A recently published retrospective analysis by a group at the University of Maryland School of Medicine has shown that preoperative anemia is a significant prognostic factor in patients with early-stage non-small-cell lung cancer (NSCLC) treated with surgery alone.
Relapse-free survival (RFS) and overall survival (OS) were calculated for 82 patients who had undergone surgical resection for stage I (n = 72) or II (n = 10) NSCLC. The 2-year RFS and OS for the entire cohort were 66% and 76.3%, respectively. Preoperative hemoglobin (Hb) level was the only factor found to significantly influence outcome in both the univariate and multivariate analyses, although there was a nonsignificant trend toward reduced survival in p53-negative patients. Multivariate analysis revealed that patients with preoperative Hb levels <12 mg/dl had significantly worse RFS and OS than those with Hb levels ≥12 mg/dl (P = 0.020 and P = 0.026, respectively).
The authors conclude that preoperative anemia is associated with increased risk of treatment failure and reduced survival, even in patients with traditionally low-risk, early-stage NSCLC. They suggest that anemia might be an indication of a more aggressive tumor and advocate further research into the prospect of using adjuvant therapy in these patients.
Rights and permissions
About this article
Cite this article
King, A. Preoperative anemia predicts poor outcome in surgically resected early-stage NSCLC patients. Nat Rev Clin Oncol 2, 489 (2005). https://doi.org/10.1038/ncponc0281
Issue Date:
DOI: https://doi.org/10.1038/ncponc0281